{"id":5790,"date":"2024-09-30T07:55:19","date_gmt":"2024-09-30T12:55:19","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5790"},"modified":"2025-06-27T10:42:26","modified_gmt":"2025-06-27T15:42:26","slug":"nanoscope-therapeutics-licenses-optogenetic-catch-technology","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","title":{"rendered":"\u062a\u0631\u0627\u062e\u064a\u0635 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0644\u062a\u0642\u0646\u064a\u0629 Optogenetic CatCh"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\u062a\u0642\u062f\u0645 \u0627\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u0645\u0628\u062a\u0643\u0631\u0629 \u0627\u0644\u0645\u062f\u0645\u062c\u0629 \u0641\u064a \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0627\u0644\u0623\u0645\u0644 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0631\u0624\u064a\u0629 \u0641\u064a \u062d\u0627\u0644\u0627\u062a \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0646\u0627\u062a\u062c\u0629 \u0639\u0646 \u0623\u0633\u0628\u0627\u0628 \u0648\u0631\u0627\u062b\u064a\u0629<\/i><\/strong><\/p>\n\n\n\u062f\u0627\u0644\u0627\u0633<\/span><\/span>,\u00a030 \u0633\u0628\u062a\u0645\u0628\u0631 2024<\/span><\/span> \u2014\u00a0\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0644\u0644\u0639\u0644\u0627\u062c\u0627\u062a<\/a>\u0623\u0639\u0644\u0646\u062a \u0627\u0644\u064a\u0648\u0645 \u0634\u0631\u0643\u0629 \u0627\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u062a\u064a \u062a\u0639\u0645\u0644 \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629 \u0648\u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a \u0627\u0644\u062b\u0627\u0646\u0648\u064a \u0644\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0628\u0642\u0639\u064a\u060c \u0623\u0646 \u0627\u0644\u0634\u0631\u0643\u0629 \u062d\u0635\u0644\u062a \u0639\u0644\u0649 \u062a\u0631\u062e\u064a\u0635 \u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 CatCh \u0645\u0646 Max Planck Innovation\u060c \u0648\u0647\u064a \u0645\u0646\u0638\u0645\u0629 \u0646\u0642\u0644 \u0627\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062a\u0627\u0628\u0639\u0629 \u0644\u062c\u0645\u0639\u064a\u0629 Max Planck. \u0648\u0627\u0633\u062a\u0646\u0627\u062f\u064b\u0627 \u0625\u0644\u0649 \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0623\u0628\u062d\u0627\u062b \u0645\u0646 \u0645\u0639\u0647\u062f Max Planck \u0644\u0644\u0641\u064a\u0632\u064a\u0627\u0621 \u0627\u0644\u062d\u064a\u0648\u064a\u0629\u060c \u0648\u0627\u0644\u0639\u0645\u0644 \u0627\u0644\u0631\u0627\u0626\u062f \u0644\u0644\u0628\u0631\u0648\u0641\u064a\u0633\u0648\u0631.\u00a0\u0625\u0631\u0646\u0633\u062a \u0628\u0627\u0645\u0628\u0631\u062c<\/span>\u00a0in the field of optogenetics, this patented technology enhances the light sensitivity of a multi-characteristic opsin (MCO-010, a tri-protein fusion complex including CatCh) developed by Nanoscope as a gene therapy to restore vision in patients suffering from genetically caused visual impairments. Nanoscope’s groundbreaking MCO platform is the first optogenetic approach to combine multiple light-sensitive components, the sum of which produces a fusion protein that is sensitive across the visible spectrum at ambient light levels with fast kinetics. Nanoscope has already successfully completed several clinical studies on MCO-010 for the two leading inherited retinal degenerative diseases: retinitis pigmentosa (RP) and Stargardt disease. The company now plans to seek approval for the therapy and expand to broad therapeutic indications.\n\n“We are excited to see the enhanced benefits of the MCO platform, which incorporates the CatCh technology from the Max Planck Institute for Biophysics, and offers new hope for restoring vision in those suffering from severe degenerative retinal conditions,” said Dr.\u00a0\u0633\u0627\u0645\u0627\u0631\u0646\u062f\u0631\u0627 \u0645\u0648\u0647\u0627\u0646\u062a\u064a<\/span>, Co-Founder & President of Nanoscope Therapeutics. “Our agreement with Max Planck Innovation allows us to transform groundbreaking scientific discoveries into effective therapeutic solutions. With efficient viral delivery of the most complex bioengineered non-mammalian MCO-010 fusion protein to treat severe degenerative retinal conditions caused by many different genetic mutations, we are on the cusp of treating patients with high unmet needs and sustainably improving their quality of life.”\n\nDr. Mareike G\u00f6ritz, Patent and Licensing manager at Max Planck Innovation, added: “The advanced properties of CatCh in combination with Nanoscope’s proprietary technology make this a very promising approach for gene therapy treatment of retinitis-related visual impairments. We are excited to follow the further development and would be delighted if patients were ultimately to benefit from this innovative approach.”\n\nBlindness and visual impairments caused by genetic eye diseases such as retinitis pigmentosa, Stargardt disease, and age-related macular degeneration pose a significant medical challenge worldwide. These diseases often lead to a progressive loss of vision and have a substantial impact on the quality of life of those affected. As current treatment options are limited, innovative approaches like the MCO platform now offer new hope. By its ability to partially restore vision through gene therapy, Nanoscope’s technology platform could represent a significant breakthrough in the treatment of these serious eye diseases.\n\n\u0627\u0644\u062a\u0637\u0628\u064a\u0642 \u0627\u0644\u0639\u0644\u0627\u062c\u064a \u0648\u0627\u0644\u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629<\/b>\n\nThe now-licensed CatCh technology has been integrated by Nanoscope Therapeutics as one of three subunits of the MCO-010 fusion protein, each of which contributes complementary light-activated properties, that together result in a treatment with the potential to restore vision in everyday settings. Nanoscope’s novel MCO-010 therapeutic approach has been successfully tested in multiple clinical studies for RP and Stargardt disease. Additionally, the MCO platform is already being tested and shown to be effective in non-human primates with geographic atrophies (GA) secondary to advanced age-related macular degeneration (AMD).\n\nThe further development and approval pathway for MCO-010 is currently being intensively reviewed. Nanoscope Therapeutics aims to obtain approval and is in discussions with the US Food and Drug Administration (FDA) to explore possible accelerated pathways to market. These efforts could help make the innovative therapy available to patients more quickly, who urgently need new treatment options.\n\nThe CatCh (calcium-transporting channelrhodopsin) technology was developed by Prof.\u00a0\u0625\u0631\u0646\u0633\u062a \u0628\u0627\u0645\u0628\u0631\u062c<\/span>\u060c \u0623\u062d\u062f \u0631\u0648\u0627\u062f \u0645\u062c\u0627\u0644 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0632\u0645\u0644\u0627\u0624\u0647 \u0641\u064a \u0645\u0639\u0647\u062f \u0645\u0627\u0643\u0633 \u0628\u0644\u0627\u0646\u0643 \u0644\u0644\u0641\u064a\u0632\u064a\u0627\u0621 \u0627\u0644\u062d\u064a\u0648\u064a\u0629. CatCh\u060c \u0648\u0647\u0648 \u0637\u0641\u0631\u0629 \u0645\u0646 Channelrhodopsin-2 \u0630\u0627\u062a \u062e\u0635\u0627\u0626\u0635 \u0645\u062d\u0633\u0646\u0629\u060c \u064a\u0648\u0641\u0631 \u0645\u0632\u0627\u064a\u0627 \u0643\u0628\u064a\u0631\u0629 \u0645\u062b\u0644 \u0627\u0644\u062d\u0631\u0643\u064a\u0629 \u0627\u0644\u0623\u0633\u0631\u0639 \u0648\u0632\u064a\u0627\u062f\u0629 \u062d\u0633\u0627\u0633\u064a\u0629 \u0627\u0644\u0636\u0648\u0621 \u0627\u0644\u0623\u0632\u0631\u0642.\n\n\u062d\u0648\u0644 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u064a\u0643\u0633 \u0625\u0646\u0643.<\/b>\n\n\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0647\u064a \u0634\u0631\u0643\u0629 \u0623\u062f\u0648\u064a\u0629 \u062d\u064a\u0648\u064a\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u062a\u0639\u0645\u0644 \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0644\u0627 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0627\u0644\u0637\u0641\u0631\u0627\u062a \u0644\u0639\u0644\u0627\u062c \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a \u0627\u0644\u062a\u064a \u062a\u0633\u0628\u0628 \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0648\u0627\u0644\u0639\u0645\u0649\u060c \u0648\u0627\u0644\u062a\u064a \u0644\u0627 \u064a\u0648\u062c\u062f \u0644\u0647\u0627 \u0639\u0644\u0627\u062c \u062d\u062a\u0649 \u0627\u0644\u0622\u0646.\u00a0\u062a\u0645 \u0627\u0644\u0625\u0639\u0644\u0627\u0646 \u0645\u0624\u062e\u0631\u064b\u0627 \u0639\u0646 \u0628\u064a\u0627\u0646\u0627\u062a 100 \u0623\u0633\u0628\u0648\u0639 \u0645\u0646<\/a>\u00a0\u0627\u0644\u0645\u0631\u062d\u0644\u0629 2\u0628\/3 \u0645\u0646 \u062a\u062c\u0631\u0628\u0629 RESTORE \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0627\u0644\u062a\u064a \u064a\u062a\u0645 \u0627\u0644\u062a\u062d\u0643\u0645 \u0641\u064a\u0647\u0627 \u0628\u0637\u0631\u064a\u0642\u0629 \u0648\u0647\u0645\u064a\u0629 \u0641\u064a \u0627\u0644\u0648\u0644\u0627\u064a\u0627\u062a \u0627\u0644\u0645\u062a\u062d\u062f\u0629 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (NCT04945772<\/a>). \u0643\u0645\u0627 \u0623\u0643\u0645\u0644\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0645\u0624\u062e\u0631\u064b\u0627 \u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0639\u0644\u0627\u062c STARLIGHT \u0644\u0639\u0644\u0627\u062c MCO-010 \u0641\u064a \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0645\u0631\u0636 Stargardt (NCT05417126<\/a>). \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0648\u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0644\u0643\u0644 \u0645\u0646 RP \u0648\u0645\u0631\u0636 Stargardt. \u062a\u0634\u0645\u0644 \u0627\u0644\u0623\u0635\u0648\u0644 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0633\u0627\u0628\u0642\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a MCO-020 \u063a\u064a\u0631 \u0627\u0644\u0641\u064a\u0631\u0648\u0633\u064a \u0628\u0627\u0644\u0644\u064a\u0632\u0631 \u0644\u0645\u0631\u0636 GA \u0627\u0644\u062b\u0627\u0646\u0648\u064a \u0644\u0640 AMD.\n\n\u0627\u0644\u0627\u062a\u0635\u0627\u0644 \u0628\u0627\u0644\u0645\u0633\u062a\u062b\u0645\u0631:<\/b>
\u0634\u0631\u0643\u0627\u0621 \u0623\u0631\u063a\u0648\u062a
(212) 600-1902
PR@nanostherapeutics.com<\/a>\n\n\u0627\u0644\u0645\u0635\u062f\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\n\n<\/div>\n<\/div>\n<\/section><\/article>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Innovative technology incorporated in Nanoscope’s gene therapy offers hope for restoring vision in genetically caused visual impairments DALLAS,\u00a0Sept. 30, 2024 —\u00a0Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy secondary to macular degeneration, today announced that the company has acquired a license for the CatCh technology […]<\/p>\n","protected":false},"author":6,"featured_media":5792,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5790","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Licenses Optogenetic CatCh Technology - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-30T12:55:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T15:42:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology\",\"datePublished\":\"2024-09-30T12:55:19+00:00\",\"dateModified\":\"2025-06-27T15:42:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\"},\"wordCount\":793,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_CatCH_PR.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\",\"name\":\"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_CatCH_PR.jpg\",\"datePublished\":\"2024-09-30T12:55:19+00:00\",\"dateModified\":\"2025-06-27T15:42:26+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_CatCH_PR.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/NSCOPE_LI_CatCH_PR.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/09\\\/30\\\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u062a\u0631\u062e\u0635 \u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0627\u0644\u062a\u0642\u0627\u0637 \u0627\u0644\u0636\u0648\u0626\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-09-30T12:55:19+00:00","article_modified_time":"2025-06-27T15:42:26+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Nanoscope Therapeutics","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"4 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology","datePublished":"2024-09-30T12:55:19+00:00","dateModified":"2025-06-27T15:42:26+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/"},"wordCount":793,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","url":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u062a\u0631\u062e\u0635 \u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0627\u0644\u062a\u0642\u0627\u0637 \u0627\u0644\u0636\u0648\u0626\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","datePublished":"2024-09-30T12:55:19+00:00","dateModified":"2025-06-27T15:42:26+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_CatCH_PR.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/09\/30\/nanoscope-therapeutics-licenses-optogenetic-catch-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Licenses Optogenetic CatCh Technology"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/5790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=5790"}],"version-history":[{"count":5,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/5790\/revisions"}],"predecessor-version":[{"id":9023,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/5790\/revisions\/9023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/5792"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=5790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=5790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=5790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}